In this issue of JAMA Ophthalmology, Hsu and coauthors1 evaluated whether there is a difference in retinal fluid using intravitreous injections with or without adjunctive topical dorzolamide-timolol drops among eyes with persistent fluid from neovascular age-related macular degeneration. The authors concluded that the study findings suggest that dorzolamide-timolol reduces macular edema compared with placebo. This conclusion was likely based on the P value of the primary outcome (P = .04) being less than the prespecified threshold for statistical significance (P < .05). However, what are the implications of drawing conclusions from P values alone?
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Glassman AR. Are P Values Enough? JAMA Ophthalmol. 2020;138(5):567–568. doi:10.1001/jamaophthalmol.2020.0710
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: